The Food and Drug Administration’s independent advisory committee will convene in open session Friday to review the latest data submitted by Pfizer and discuss whether a booster dose is safe enough for widespread use and whether it’s necessary and effective at improving protection levels against COVID-19.
Their vote will be non-binding — the FDA is not required to follow the Vaccines and Related Biological Products Advisory Committee’s (VRBPAC) recommendations — but they generally do so.
